Details

Autor(en) / Beteiligte

• Bach, Peter B
• Giralt, Sergio A
• Saltz, Leonard B

Titel

FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug

Ist Teil von

• JAMA : the journal of the American Medical Association, 2017-11, Vol.318 (19), p.1861

Ort / Verlag

United States: American Medical Association

Erscheinungsjahr

2017

Quelle

PAIS Index

Beschreibungen/Notizen

• Approval of the drug tisagenledeucel (Kymriah; Novartis) by the US Food and Drug Administration (FDA) for the treatment of pediatric and young adult acute lymphoblastic leukemia, definitively shattered oncology drug pricing norms for its list of price $475 000. The price of this therapy should serve as a reminder that future revenue outlooks for a pharmaceutical company are in part related to the ability to generate many millions in revenue even when few patients benefit from the new therapies. The price of $475 000 for a single treatment with tisagenledeucel is difficult to put into context because expensive cancer treatments typically cost $10 000 to $20 000 per month and reflect prices that have already increased more rapidly than the benefits they have provided patients over the past several decades.